Should we redefine the Phoenix criteria for biochemical recurrence after primary radiotherapy?
The Phoenix criteria no longer align with the capabilities of current diagnostic and prognostic tools. Redefining BCR using dynamic PSA metrics and advanced imaging could facilitate timely salvage treatment in patients at a high risk and allow surveillance strategies in those unlikely to progress. Prospective validation is warranted to inform future clinical guidelines.
Authors
- Peter N. Wiklund (ORCID: https://orcid.org/0000-0001-6497-4697)
- Ugo Giovanni Falagario (ORCID: https://orcid.org/0000-0002-1152-3005)
- Francesco Pellegrino (ORCID: https://orcid.org/0000-0002-7828-6876)
Institutions
- University of Foggia (IT)
- University of Milan (IT)
- Karolinska Institutet (SE)
- Ospedale San Paolo (IT)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Current Opinion in Urology
- Published
- 2025-07-04
- DOI
- https://doi.org/10.1097/mou.0000000000001313
- Citations
- 3
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56